Méan Marie, Aujesky Drahomir, Lämmle Bernhard, Gerschheimer Christiane, Trelle Sven, Angelillo-Scherrer Anne
Division of General Internal Medicine, Bern University Hospital and University of Bern, 3010, Bern, Switzerland,
J Thromb Thrombolysis. 2013 Nov;36(4):484-91. doi: 10.1007/s11239-013-0922-z.
In the field of thrombosis and haemostasis, many preanalytical variables influence the results of coagulation assays and measures to limit potential results variations should be taken. To our knowledge, no paper describing the development and maintenance of a haemostasis biobank has been previously published. Our description of the biobank of the Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+) is intended to facilitate the set-up of other biobanks in the field of thrombosis and haemostasis. SWITCO65+ is a multicentre cohort that prospectively enrolled consecutive patients aged ≥65 years with venous thromboembolism at nine Swiss hospitals from 09/2009 to 03/2012. Patients will be followed up until December 2013. The cohort includes a biobank with biological material from each participant taken at baseline and after 12 months of follow-up. Whole blood from all participants is assayed with a standard haematology panel, for which fresh samples are required. Two buffy coat vials, one PAXgene Blood RNA System tube and one EDTA-whole blood sample are also collected at baseline for RNA/DNA extraction. Blood samples are processed and vialed within 1 h of collection and transported in batches to a central laboratory where they are stored in ultra-low temperature archives. All analyses of the same type are performed in the same laboratory in batches. Using multiple core laboratories increased the speed of sample analyses and reduced storage time. After recruiting, processing and analyzing the blood of more than 1,000 patients, we determined that the adopted methods and technologies were fit-for-purpose and robust.
在血栓形成与止血领域，许多分析前变量会影响凝血检测结果，因此应采取措施限制潜在的结果差异。据我们所知，此前尚未发表过描述止血生物样本库建立与维护的论文。我们对瑞士老年静脉血栓栓塞患者队列（SWITCO65+）生物样本库的描述旨在促进血栓形成与止血领域其他生物样本库的建立。SWITCO65+是一个多中心队列，于2009年9月至2012年3月在瑞士九家医院前瞻性纳入了年龄≥65岁的连续静脉血栓栓塞患者。患者将随访至2013年12月。该队列包括一个生物样本库，其中保存了每位参与者在基线时以及随访12个月后的生物样本。所有参与者的全血都用标准血液学检测板进行检测，这需要新鲜样本。在基线时还收集了两管血沉棕黄层、一管PAXgene Blood RNA系统管和一份EDTA全血样本用于RNA/DNA提取。血液样本在采集后1小时内进行处理并装瓶，然后分批运至中央实验室，在那里保存在超低温档案库中。同一类型的所有分析都在同一实验室分批进行。使用多个核心实验室提高了样本分析速度并减少了储存时间。在招募、处理和分析了1000多名患者的血液后，我们确定所采用的方法和技术是适用且可靠的。
